Drug Trial Radar · NCT06120140
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
305
Actual
Start
Feb 16, 2024
Primary completion
May 31, 2027
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade \>=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IVDrug
Amivantamab will be administered.
Amivantamab SCDrug
Amivantamab will be administered as SC injection.
LazertinibDrug
Lazertinib tablet will be administered orally.
DoxycyclineDrug
Doxycycline tablet will be administered orally.
MinocyclineDrug
Minocycline capsule will be administered orally.
ClindamycinDrug
Clindamycin lotion will be used as topical application on the scalp.
ChlorhexidineDrug
Chlorhexidine solution will be used as topical application on hands and feet.
Noncomedogenic skin moisturizerOther
Noncomedogenic skin moisturizer will be used as topical application.
RuxolitinibOther
Ruxolitinib will be used to the affected skin area.
TacrolimusOther
Tacrolimus will be used as topical application to the affected skin area.
Zinc gluconateDrug
Zinc gluconate tablet will be administered.
PropranololDrug
Propranolol tablet will be administered.
TimololDrug
Timolol will be used to the affected skin area.
ClobetasolDrug
Clobetasol shampoo will be used on the scalp.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer TreatmentTime frame: Up to 12 weeks after initiation of anticancer treatment
Locations
93 sites in 11 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Center
Chandler, Arizona
City of Hope
Duarte, California
Providence Fullerton
Fullerton, California
Los Angeles Cancer Network
Glendale, California
City of Hope Seacliff
Huntington Beach, California
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California
City of Hope Long Beach Elm
Long Beach, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Keck Hospital of USC
Los Angeles, California
USC Norris Oncology Hematology Newport Beach
Newport Beach, California
Kaiser Permanente Oakland Medical Center
Oakland, California
Kaiser Permanente Roseville Medical Center
Roseville, California
Kaiser Permanente San Francisco Medical Center
San Francisco, California
Kaiser Permanente Santa Clara Medical Center
Santa Clara, California
City of Hope South Pasadena
South Pasadena, California
Kaiser Permanente Northern California
Vallejo, California
Kaiser Permanente Walnut Creek Medical Center
Walnut Creek, California
University Cancer & Blood Center
Athens, Georgia
Hope and Healing Care
Hinsdale, Illinois
Oncology Hematology Associates
Springfield, Missouri
Renown Health Medical Oncology
Reno, Nevada
Hunterdon Hematology Oncology
Flemington, New Jersey
Clinical Research Alliance Inc
Westbury, New York
Regional Medical Oncology Center
Wilson, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Virginia Cancer Specialists
Fairfax, Virginia
Valley Medical Center
Renton, Washington
Gundersen Health System
West Salem, Wisconsin
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
IADT Instituto Argentino de Diagnostico y Tratamiento
CABA, Argentina
Centro Medico Austral
Capital Federal, Argentina
Hospital Italiano de La Plata
La Plata, Argentina
Hospital Privado de la Comunidad
Mar del Plata, Argentina
CTO Centro De Tratamento Oncologico LTDA
Belém, Brazil
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, Brazil
Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Fundacao Doutor Amaral Carvalho
Jaú, Brazil
Hospital Nossa Senhora da Conceicao S A
Porto Alegre, Brazil
Nucleo de Oncologia da Bahia Oncoclinicas
Salvador, Brazil
Hospital Ana Nery Santa Cruz do Sul
Santa Cruz do Sul, Brazil
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.